Description
Developer of an anti-gene drug platform. The company develops a computational design of modular polymers that bind a specific sequence of DNA.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Out of Business | 01-Apr-2018 | Completed | Out of Business | |||
1. Accelerator/Incubator | Completed | Generating Revenue |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20130231480-A1 | Sequence specific double-stranded dna/rna binding compounds and uses thereof | Abandoned | 22-Jul-2010 | 0000000000 | |
EP-2596102-A2 | Sequence specific double-stranded dna/rna binding compounds and uses thereof | Withdrawn | 22-Jul-2010 | 0000000000 | |
US-20100284959-A1 | Sequence specific double-stranded dna/rna binding compounds and uses thereof | Abandoned | 23-Jan-2008 | C07D473/16 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Mizied Falah Ph.D | Co-Founder & Chief Technology Officer | ||
Anwar Rayan Ph.D | Co-Founder & Chief Executive Officer |